- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cohance Lifesciences Limited (COHA)
Cohance Lifesciences Limited stock price live, this page displays NSE COHA stock exchange data. View the COHA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cohance Lifesciences Limited real time stock price chart below.
What Is the Cohance Lifesciences Limited Stock Price Today?
The Cohance Lifesciences Limited stock price today is 451.30.
What Is the Stock Symbol for Cohance Lifesciences Limited?
The stock symbol for Cohance Lifesciences Limited is "COHA."
What Stock Exchange Does Cohance Lifesciences Limited Trade On?
Cohance Lifesciences Limited is listed and trades on the NSE stock exchange.
Is Cohance Lifesciences Limited a Good Stock to Buy?
Determining whether Cohance Lifesciences Limited—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the COHA quote. (ISIN: INE03QK01018)
What Is the Cohance Lifesciences Limited Stock Price Today?
The Cohance Lifesciences Limited stock price today is 451.30.
What Is the Stock Symbol for Cohance Lifesciences Limited?
The stock symbol for Cohance Lifesciences Limited is "COHA."
What Stock Exchange Does Cohance Lifesciences Limited Trade On?
Cohance Lifesciences Limited is listed and trades on the NSE stock exchange.
Is Cohance Lifesciences Limited a Good Stock to Buy?
Determining whether Cohance Lifesciences Limited—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the COHA quote. (ISIN: INE03QK01018)
451.30
+7.30(+1.64%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
435.00
454.85
52 wk Range
266.70
917.85
COHA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
435.00454.85
52 wk Range
266.70917.85
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
COHA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
508.33
Upside
+12.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Pharmaceuticals industry
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
1 Hold
4 Sell
Ratings:
9 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 508.33
(+12.64% Upside)
Cohance Lifesciences Limited Earnings Call Summary for Q1/2027
- Q1 FY2027 revenue fell 23% YoY to $4.22B, missing estimates by $197M; adjusted EBITDA margin compressed to 2.2% in weakest quarter ever.
- NJ Bio losses dragged consolidated profitability while Sapala oligonucleotides surged 2.5x YoY; API Plus remained resilient despite margin pressure.
- Management guided Q1 as year's low point, expects sequential Q2 improvement and YoY growth resuming in second half of fiscal 2027.
- Pharma CDMO pipeline strengthening with two molecules entering commercial supply; seven new API Plus filings planned for FY2027.
- Stock rose 1.1% to $429.45 as investors looked past weak results; shares remain 59% below 52-week high amid execution and funding risks.
Last Updated: 2026-08-05, 10:46 a/m
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
-0.62 / -1.30
Revenue / Forecast
4.22B / 4.42B
Compare COHA to Peers and Sector
Metrics to compare | COHA | Peers Peers - average of corresponding metrics from companies closely matching COHA: SYNGENE, JUBLPHARMA, 524790, AKUMS, SYMBIOTEC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCOHAPeersSector |
|---|---|---|---|---|
P/E Ratio | 162.5x | 45.0x | −0.4x | |
PEG Ratio | - | 0.52 | 0.00 | |
Price/Book | 4.4x | 4.6x | 2.6x | |
Price / LTM Sales | 8.1x | 7.1x | 3.0x | |
Upside (Analyst Target) | 12.6% | 7.1% | 56.4% | |
Fair Value Upside | Unlock | 0.3% | 7.9% | Unlock |
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cohance Lifesciences (COHA) Stock Price Today?
The Cohance Lifesciences stock price today is 451.30 INR.
What Stock Exchange Does Cohance Lifesciences Trade On?
Cohance Lifesciences is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Cohance Lifesciences?
The stock symbol for Cohance Lifesciences is "COHA."
What Is the Cohance Lifesciences Market Cap?
As of today, Cohance Lifesciences market cap is 172.65B INR.
When Is the Next Cohance Lifesciences Earnings Date?
Cohance Lifesciences will release its next earnings report on Nov 02, 2026.
From a Technical Analysis Perspective, Is COHA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Cohance Lifesciences Stock Split?
Cohance Lifesciences has split 1 times.
How Many Employees Does Cohance Lifesciences Have?
Cohance Lifesciences has 1212 employees.
What is the current trading status of Cohance Lifesciences (COHA)?
As of Oct 02, 2026, Cohance Lifesciences (COHA) is trading at a price of 451.30 INR, with a previous close of 451.30 INR. The stock has fluctuated within a day range of 435.00 INR to 454.85 INR, while its 52-week range spans from 266.70 INR to 917.85 INR.
What Is Cohance Lifesciences (COHA) Price Target According to Analysts?
The average 12-month price target for Cohance Lifesciences is 508.33 INR, with a high estimate of 1150 INR and a low estimate of 315 INR. 4 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Neutral. The stock has an +12.64% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.